Kobo Biotech (BOM:531541) Debt-to-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Kobo Biotech Debt-to-Asset?

Kobo Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Kobo Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Kobo Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₹0.00 Mil.

Kobo Biotech Debt-to-Asset Historical Data

The historical data trend for Kobo Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kobo Biotech Debt-to-Asset Chart

Kobo Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

Get a 7-Day Free Trial

0.99

1.06

1.13

1.78

1.86

Kobo Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															-	1.86	-	1.91	-

Competitive Comparison of Kobo Biotech's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Kobo Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kobo Biotech's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kobo Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Kobo Biotech's Debt-to-Asset falls into.

Kobo Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Kobo Biotech's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1071.811	+	326.6)	/	753.3
	=	1.86

Kobo Biotech's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0
	=	N/A

Kobo Biotech (BOM:531541) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Kobo Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Kobo Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Kobo Biotech (BOM:531541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kobo Biotech Ltd (BOM:531541) » Definitions » Debt-to-Asset

Traded in Other Exchanges

N/A

Address

Saki Vihar Road, Unit 104, HYDE Park, Opp. Ansa Industrial Estate, Andheri (East), Mumbai, MH, IND, 400 072

Website

http://www.kobobiotech.com

Kobo Biotech Ltd is a pharmaceutical company. Its business comprises the manufacturing and sale of APIs (Active Pharmaceutical Ingredients) based on fermentation technology and Intermediates to pharmaceutical companies.

Kobo Biotech (BOM:531541) Headlines

No Headlines